- Home
- KLTO vs SNGX Comparison
KLTO vs SNGX Comparison
Compare KLTO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- SNGX
- Stock Information
- Founded
- KLTO 2019
- SNGX 1987
- Country
- KLTO United States
- SNGX United States
- Employees
- KLTO N/A
- SNGX N/A
- Industry
- KLTO
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- SNGX Health Care
- Exchange
- KLTO NYSE
- SNGX Nasdaq
- Market Cap
- KLTO 8.3M
- SNGX 9.6M
- IPO Year
- KLTO N/A
- SNGX 1987
- Fundamental
- Price
- KLTO $0.48
- SNGX $3.16
- Analyst Decision
- KLTO
- SNGX
- Analyst Count
- KLTO 0
- SNGX 0
- Target Price
- KLTO N/A
- SNGX N/A
- AVG Volume (30 Days)
- KLTO 992.6K
- SNGX 46.1K
- Earning Date
- KLTO 02-15-2025
- SNGX 11-08-2024
- Dividend Yield
- KLTO N/A
- SNGX N/A
- EPS Growth
- KLTO N/A
- SNGX N/A
- EPS
- KLTO N/A
- SNGX N/A
- Revenue
- KLTO N/A
- SNGX $364,183.00
- Revenue This Year
- KLTO N/A
- SNGX N/A
- Revenue Next Year
- KLTO N/A
- SNGX $76.64
- P/E Ratio
- KLTO N/A
- SNGX N/A
- Revenue Growth
- KLTO N/A
- SNGX N/A
- 52 Week Low
- KLTO $0.26
- SNGX $1.83
- 52 Week High
- KLTO $13.10
- SNGX $19.20
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- SNGX 41.70
- Support Level
- KLTO N/A
- SNGX $2.93
- Resistance Level
- KLTO N/A
- SNGX $3.35
- Average True Range (ATR)
- KLTO 0.00
- SNGX 0.19
- MACD
- KLTO 0.00
- SNGX -0.01
- Stochastic Oscillator
- KLTO 0.00
- SNGX 37.10
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).